Cephalon Looks Cheap After Today's Sell Off (CEPH)

Yesterday after the close of trading, Cephalon CEPH released its quarterly earnings numbers. The report was quite strong, except for Q3 revenue guidance was on the light side. It appears that this is the reason investors are selling the stock today. CEPH has fallen 8.52% to $57.54 on Wednesday. From a pure valuation standpoint, this stock looks very cheap. It trades at a trailing P/E of 11.51, a forward P/E of 7.71 and a PEG ratio of 0.96. After today's massacre, CEPH may be worth a look. Cephalon, Inc. is an international biopharmaceutical company engaged in the discovery, development and commercialization of products in four core therapeutic areas: central nervous system (CNS), pain, oncology and inflammatory disease.